| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 2 nM (FLAP)[1].
|
|---|---|
| ln Vitro |
Leukotriene synthesis is dose-dependently inhibited by atuliflapon [1]. For LTB4, atuliflapon exhibits an IC50 of 39 nM[1].
|
| ln Vivo |
The half-life (t1/2) of AtuLiflapon administered intravenously is 0.45 hours in rats and 2.1 hours in dogs [1]. In mouse blood, AtuLiflapon does not exhibit suppression of 5-LO pathway activity [1].
|
| References | |
| Additional Infomation |
Atuliflapon is currently undergoing the clinical trial NCT05251259 (a study evaluating the efficacy and safety of atuliflapon in the treatment of moderate to severe uncontrolled asthma).
5-Lipoxygenase-activated protein inhibitor |
| Molecular Formula |
C24H26N6O3
|
|---|---|
| Molecular Weight |
446.501644611359
|
| Exact Mass |
446.206
|
| CAS # |
2041075-86-7
|
| PubChem CID |
122678117
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
755
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(C1C=CC(C2C=C(C)NN=2)=CC=1)[C@@H]1CCCC[C@H]1C(NC1C=NN2CCNC(C2=1)=O)=O
|
| InChi Key |
ROTWSDMXHVGAHZ-QZTJIDSGSA-N
|
| InChi Code |
InChI=1S/C24H26N6O3/c1-14-12-19(29-28-14)15-6-8-16(9-7-15)22(31)17-4-2-3-5-18(17)23(32)27-20-13-26-30-11-10-25-24(33)21(20)30/h6-9,12-13,17-18H,2-5,10-11H2,1H3,(H,25,33)(H,27,32)(H,28,29)/t17-,18-/m1/s1
|
| Chemical Name |
(1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]-N-(4-oxo-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazin-3-yl)cyclohexane-1-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (279.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL | |
| 5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL | |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05251259
Conditions:AsthmaLink: https://clinicaltrials.gov/ct2/show/NCT04601467
Conditions:Acute Coronary SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT04492722
Conditions:Chronic Kidney Disease
Title:Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers
Status:Completed
updateDate:2021-12-06
Ctid:NCT04734275
Link: https://clinicaltrials.gov/ct2/show/NCT04734275
Conditions:Chronic Kidney DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT03317002
Conditions:Coronary Artery DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04492709
Conditions:Cardiovascular DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04210388
Conditions:Coronary Artery Disease (CAD)Link: https://clinicaltrials.gov/ct2/show/NCT02632526
Conditions:Healthy Male Subjects|Cardiovascular DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT03400488
Conditions:Coronary Artery DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT03420092
Conditions:Coronary Artery DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT02963116
Conditions:High Risk Coronary Artery DiseaseProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
